Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
Compare PET/CT and MRI for the early detection of bone metastases of prostate cancer: diagnostic performance and impact on the patient management.Determine the lowest cost strategy according to the precise clinical circumstances.

Detailed Description
-----------------
In patients with high risk prostate cancer and high PSA levels, PET/CT with fluoride (18F) and FLUOROCHOLINE (18F) and whole-body MRI will be performed within one month. Data of a 6 month follow-up after those examination will be made available to a panel of independent experts. They will determine the standard of truth (SOT) concerning the invasion of the skeleton and also of soft tissue by prostate cancer tissue, the impact of each imaging modality on patient management and the adequacy of the decisions. In some cases (anti-hormone treatment without histology), it will not be possible to determine the SOT. By comparison of the results of blind readings for each imaging modality with the standard of truth, the diagnostic performance will be determined. By simulation, several strategies will be constructed concerning the best examinations to be performed and the sequence according to the precise clinical circumstances. Their cost and effectiveness will be evaluated.

Official Title
-----------------
Role of PET/CT With Fluorine-18 Tracers and of Diffusion Weighted Whole-body MRI in the Early Detection of Bone Metastases in Prostate Cancer

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Device: performance of PET/CT and whole-body MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 Histologically proven prostate cancer. Abnormal plasmatic level of prostate specific antigen dating less than 3 months, initial Gleason score available Written informed consent. Exclusion Criteria: Other active cancer or bone infection. Chemotherapy or change in hormone therapy since the last PSA assay Contraindication to MRI without contrast agent (claustrophobia, pace maker, metallic foreign body, some cardiac valves). Metallic joint prostheses are NOT a contraindication. Allergic reaction to radiopharmaceuticals that will be used. Patient who seems not capable of staying in the gantry of the machines during the examinations without moving.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PET/CT and MRI<br>all patients will benefit from PET/CT and MRI | Device: performance of PET/CT and whole-body MRI<br>* For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bone metastases | Follow up data (histology, imaging, PSA levels) during 6 months to determine the standard of truth and the adequacy of the management decided on basis of imaging modalities. | within 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Comparison of imaging modalities, Impact on patient management, Optimisation of cost of the diagnostic strategy